Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18248250 | 0.85 | RIPK1 (0.73) | RAB9ANPC1SMN1; SMN2RIPK1 | |
| SCHEMBL30175822 | 0.85 | ALDH1A1 (0.53) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30175857 | 0.82 | RIPK1 (0.54) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30175855 | 0.82 | RIPK1 (0.54) | RIPK1EGFRKDM4EALDH1A1 | |
| SCHEMBL30175812 | 0.82 | RIPK1 (0.72) | RAB9ANPC1SMN1; SMN2MAOAMAOB | |
| SCHEMBL24351038 | 0.81 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL23808149 | 0.81 | NPC1 (0.52) | RAB9ANPC1SMN1; SMN2MAOAMAOB | |
| SCHEMBL30175816 | 0.79 | RIPK1 (0.77) | RIPK1 | |
| SCHEMBL9377762 | 0.78 | RIPK1 (0.74) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30175846 | 0.71 | RAD51 (0.46) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | TES PHARMA S.R.L. (IT) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052747-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS | RAD51, BRCA1, FANCI | RAB9A 1364/4885NPC1 949/4885SMN1; SMN2 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.